



CorEvitas IBD Registry
Quarterly Report
August 16, 2022

Table of Contents

Table 1. Overview of the Registry	4
Table 2. Patients by Active Status in the Registry	5
Table 3. Length of Patient Total Follow-up (years).....	6
Table 4a. Therapy Use at or after Enrollment ^a	7
Table 4b. Therapy use at Enrollment ^a	8
Table 4c. Therapy Initiations at or after Enrollment ^a	9
Table 4d. Therapy Initiations at or after Enrollment with at least 1 follow-up visit ^{a, c}	10
Table 5. Patient Characteristics at Enrollment for all Patients in the Registry	11
Table 6. Patient Characteristics at last CorEvitas Visit for all Patients in the registry....	12

The CorEvitas IBD Registry is a prospective, non-interventional, research study for patients with IBD under the care of a certified gastroenterologist launched in May 2017. Patients are enrolled into the registry if they meet all of the following inclusion criteria:

1. Has been diagnosed with Crohn's disease or Ulcerative colitis by a gastroenterologist.
2. Is at least 18 years of age or older.
3. Is willing to provide Personal Information.
4. Meets ONE (1) of the following sets of conditions at the time of enrollment (A or B):
 - A.**
 - Has a diagnosis of Ulcerative colitis
 - Has never taken a Biologic or Small Molecule medication (i.e. no past exposure to either drug type)
 - Has started taking a new Eligible Immunosuppressant Medication within the 12 months prior to the Enrollment Visit OR is prescribed or starting a new Eligible Immunosuppressant Medication at the Enrollment Visit. A new medication is a medication that the patient has never taken before.
 - OR**
 - B.**
 - Has a diagnosis of Ulcerative colitis or Crohn's disease
 - Has started taking a new Eligible Biologic or Eligible Small Molecule Medication within the 12 months prior to the Enrollment Visit OR is prescribed or starting a new Eligible Biologic or Eligible Small Molecule Medication at the Enrollment Visit. A new medication is a medication that the patient has never taken before.

The following quarterly report provides the aggregate data from contributing registry providers and sites from the launch of the registry: May 3, 2017 to 2022-08-16.

Note: Patient diagnosis may change at follow-up visits. Tables 1-6 utilize patient's most recent diagnosis. Under the current inclusion criteria, patients with a diagnosis of Indeterminate Colitis are not eligible for enrollment. Only patients with a current diagnosis of Ulcerative Colitis or Crohn's Disease are included in this report, x patients with Indeterminate Colitis have been excluded.

Table 1. Overview of the Registry

Table 2. Patients by Active Status in the Registry

Table 3. Length of Patient Total Follow-up (years)

Tables 4a, 4b, 4c and 4d provide counts of therapy use within the CorEvitas IBD Registry. The counts in each table differ depending on when the patient starts therapy relative to enrollment. Refer to each table's footnote for specific definition.

Table 4a. Therapy Use at or after Enrollment^a

Table 4b. Therapy use at Enrollment^a

Table 4c. Therapy Initiations at or after Enrollment^a

Table 4d. Therapy Initiations at or after Enrollment with at least 1 follow-up visit^{a, c}

Table 5. Patient Characteristics at Enrollment for all Patients in the Registry

Table 6. Patient Characteristics at last CorEvitas Visit for all Patients in the registry